Reply to: Eruptive Bowen's disease in a patient on pembrolizumab for Hodgkin's lymphoma

Australas J Dermatol. 2022 May;63(2):e195-e197. doi: 10.1111/ajd.13798. Epub 2022 Feb 1.

Authors

Joana Cruañes-Monferrer¹, Francisco Martínez-Díaz², Juan Monte-Serrano³, Mar García-García⁴, María Encarnación Giménez Cortés¹

Affiliations

¹ Department of Dermatology, Reina Sofía University Hospital, Murcia, Spain.
² Department of Pathology, Reina Sofía University Hospital, Murcia, Spain.
³ Department of Dermatology, Lozano Blesa University Hospital, Zaragoza, Spain.
⁴ Department of Pathology, Lozano Blesa University Hospital, Zaragoza, Spain.

PMID: 35103311
DOI: 10.1111/ajd.13798

No abstract available

Keywords: CXCR3; keratinocyte; pembrolizumab; proliferation..

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Bowen's Disease* / pathology
Exanthema*
Hodgkin Disease* / drug therapy
Humans
Skin Neoplasms* / chemically induced
Skin Neoplasms* / drug therapy
Skin Neoplasms* / pathology

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab